amitriptyline has been researched along with Diabetic Neuropathies in 60 studies
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.
amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.
Diabetic Neuropathies: Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Low-dose naltrexone exhibited similar efficacy and a superior safety profile compared with amitriptyline in painful diabetic neuropathy." | 9.41 | Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: A randomized, double-blind, active-control, crossover clinical trial. ( Bansal, D; Bhansali, AK; Chakrabarti, A; Dutta, P; Hota, D; Srinivasan, A, 2021) |
| "To compare the efficacy and safety of pregabalin and amitriptyline in alleviating pain associated with diabetic peripheral neuropathy." | 9.14 | Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial. ( Bansal, D; Bhansali, A; Chakrabarti, A; Dutta, P; Hota, D, 2009) |
| "The objective of this study was to compare the efficacy and tolerability of gabapentin and amitriptyline monotherapy in painful diabetic neuropathy." | 9.09 | Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. ( Buffa, C; Chiroli, S; Dallocchio, C; Mazzarello, P, 2000) |
| "To determine the efficacy of gabapentin compared with amitriptyline in treating diabetic peripheral neuropathy pain." | 9.09 | Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. ( Leckband, SG; Moorhouse, DF; Morello, CM; Sahagian, GA; Stoner, CP, 1999) |
| "From the present results and the literature, it is concluded that tricyclic antidepressants with a pharmacologic profile similar to amitriptyline are the most effective drugs in the treatment of polyneuropathy pain in both diabetic and nondiabetic patients." | 9.08 | A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. ( Arnqvist, H; Boivie, J; Holmgren, H; Lindström, T; Thorell, LH; Vrethem, M, 1997) |
| "Amitriptyline reduces the pain caused by peripheral-nerve disease, but treatment is often limited by side effects related to the drug's many pharmacologic actions." | 9.07 | Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. ( Dubner, R; Lynch, SA; Max, MB; Muir, J; Shoaf, SE; Smoller, B, 1992) |
| "We conducted a double-blind, placebo-controlled, crossover study of the effectiveness of amitriptyline and fluphenazine in alleviating the pain of diabetic peripheral neuropathy in six diabetic patients." | 9.06 | A trial of amitriptyline and fluphenazine in the treatment of painful diabetic neuropathy. ( Chappell, DA; Dere, WH; Gertz, BJ; Grunfeld, C; Karam, JH; Klein, RF; Lavin, TN; Mendel, CM, 1986) |
| "Seven patients with diabetes of ten to 24 years' duration and renal insufficiency were treated with fluphenazine and amitriptyline in an attempt to control severe pain in the extremities." | 7.66 | Diabetic neuropathic pain: control by amitriptyline and fluphenazine in renal insufficiency. ( Drager, AM; Mitas, JA; Mosley, CA, 1983) |
| "Amitriptyline is a tricyclic antidepressant agent which also has analgesic properties." | 6.39 | Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. ( Bryson, HM; Wilde, MI, 1996) |
| "In mixed neuropathic pain, case series reports suggest a favourable response rate, but are limited by trial characteristics." | 5.43 | Topical amitriptyline and ketamine for post-herpetic neuralgia and other forms of neuropathic pain. ( Sawynok, J; Zinger, C, 2016) |
| "Low-dose naltrexone exhibited similar efficacy and a superior safety profile compared with amitriptyline in painful diabetic neuropathy." | 5.41 | Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: A randomized, double-blind, active-control, crossover clinical trial. ( Bansal, D; Bhansali, AK; Chakrabarti, A; Dutta, P; Hota, D; Srinivasan, A, 2021) |
| "To compare the efficacy and safety of pregabalin and amitriptyline in alleviating pain associated with diabetic peripheral neuropathy." | 5.14 | Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial. ( Bansal, D; Bhansali, A; Chakrabarti, A; Dutta, P; Hota, D, 2009) |
| "The objective of this study was to compare the efficacy and tolerability of gabapentin and amitriptyline monotherapy in painful diabetic neuropathy." | 5.09 | Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. ( Buffa, C; Chiroli, S; Dallocchio, C; Mazzarello, P, 2000) |
| "To determine the efficacy of gabapentin compared with amitriptyline in treating diabetic peripheral neuropathy pain." | 5.09 | Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. ( Leckband, SG; Moorhouse, DF; Morello, CM; Sahagian, GA; Stoner, CP, 1999) |
| "From the present results and the literature, it is concluded that tricyclic antidepressants with a pharmacologic profile similar to amitriptyline are the most effective drugs in the treatment of polyneuropathy pain in both diabetic and nondiabetic patients." | 5.08 | A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. ( Arnqvist, H; Boivie, J; Holmgren, H; Lindström, T; Thorell, LH; Vrethem, M, 1997) |
| "Amitriptyline reduces the pain caused by peripheral-nerve disease, but treatment is often limited by side effects related to the drug's many pharmacologic actions." | 5.07 | Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. ( Dubner, R; Lynch, SA; Max, MB; Muir, J; Shoaf, SE; Smoller, B, 1992) |
| "We conducted a double-blind, placebo-controlled, crossover study of the effectiveness of amitriptyline and fluphenazine in alleviating the pain of diabetic peripheral neuropathy in six diabetic patients." | 5.06 | A trial of amitriptyline and fluphenazine in the treatment of painful diabetic neuropathy. ( Chappell, DA; Dere, WH; Gertz, BJ; Grunfeld, C; Karam, JH; Klein, RF; Lavin, TN; Mendel, CM, 1986) |
| " The aim of the present investigation was to evaluate, firstly, the peripheral and systemic effects of amitriptyline on tactile allodynia in the streptozotocin (STZ)-induced diabetic rat model of neuropathic pain and, secondly, whether caffeine coadministration affects the actions of amitriptyline." | 3.71 | Involvement of adenosine in the anti-allodynic effect of amitriptyline in streptozotocin-induced diabetic rats. ( Aslantas, A; Dokmeci, I; Firat, Z; Karadag, HC; Tamer, M; Ulugol, A, 2002) |
| "Seven patients with diabetes of ten to 24 years' duration and renal insufficiency were treated with fluphenazine and amitriptyline in an attempt to control severe pain in the extremities." | 3.66 | Diabetic neuropathic pain: control by amitriptyline and fluphenazine in renal insufficiency. ( Drager, AM; Mitas, JA; Mosley, CA, 1983) |
| "Diabetic peripheral neuropathic pain (DPNP) is common and often distressing." | 3.11 | Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomise ( Ahmed, SH; Alam, U; Bennett, DL; Bouhassira, D; Bradburn, M; Cooper, C; Devers, M; Gandhi, R; Glover, R; Gouni, R; Hariman, C; Horspool, M; Johnson, M; Jude, EB; Julious, S; Loban, A; Maguire, D; McDougall, C; Petrie, J; Rajbhandari, S; Rayman, G; Rice, ASC; Selvarajah, D; Sharma, S; Sloan, G; Sutherland, K; Tesfaye, S; Tsatlidis, V; Turton, E; Vas, P; Waterhouse, S; White, D, 2022) |
| "As there are few differences between the two treatments in efficacy, lamotrigine 25 mg twice daily might be the first choice as it is associated with fewer adverse effects in our population." | 2.73 | Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy. ( Bhansali, A; Hota, D; Jose, VM; Pandhi, P, 2007) |
| "Duloxetine hydrochloride is a dual reuptake inhibitor of both serotonin and norepinephrine." | 2.72 | Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. ( D'Souza, DN; Iyengar, S; Pritchett, YL; Raskin, J; Smith, TR; Wernicke, JF; Wong, K, 2006) |
| "Amitriptyline was superior to placebo in relieving pain in weeks 3 through 6." | 2.66 | Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. ( Culnane, M; Dubner, R; Gracely, RH; Max, MB; Schafer, SC; Smoller, B; Walther, DJ, 1987) |
| "Severe chronic neuropathic pain is a challenge to treat, and due to adverse effects of classical oral medication, optimal and effective dose levels are difficult to reach." | 2.48 | High doses of topical amitriptyline in neuropathic pain: two cases and literature review. ( Hesselink, JM; Kopsky, DJ, 2012) |
| "The pathogenesis of diabetic neuropathies is not clear, but possibly involves a complex of metabolic factors inducing nerve ischaemia." | 2.43 | [Diabetic neuropathy--a clinical review]. ( Berg, TJ; Nøkleby, K, 2005) |
| "Desipramine has been shown in one small study to have efficacy equal to amitriptyline." | 2.40 | Tricyclic antidepressant use in diabetic neuropathy. ( Joss, JD, 1999) |
| "Amitriptyline is a tricyclic antidepressant agent which also has analgesic properties." | 2.39 | Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. ( Bryson, HM; Wilde, MI, 1996) |
| " However, sitagliptin was observed to have no effect when administered alone or in combination with the other three drugs." | 1.43 | Drug combinations in diabetic neuropathic pain: an experimental validation. ( Mehta, AK; Tripathi, CD; Yadav, AM, 2016) |
| "In mixed neuropathic pain, case series reports suggest a favourable response rate, but are limited by trial characteristics." | 1.43 | Topical amitriptyline and ketamine for post-herpetic neuralgia and other forms of neuropathic pain. ( Sawynok, J; Zinger, C, 2016) |
| "Amitriptyline was the most commonly used agent for treatment of diabetes related neuropathic pain with Duloxetine much less used." | 1.40 | Socioeconomic deprivation independently predicts symptomatic painful diabetic neuropathy in type 1 diabetes. ( Anderson, SG; Dunn, G; Heald, AH; Malipatil, NS; Roberts, H, 2014) |
| "Amitriptyline was the only antidepressant prescribed commonly as a first-line treatment." | 1.39 | An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population. ( Carroll, D; Gabriel, ZL; Hall, GC; McQuay, HJ; Morant, SV, 2013) |
| "(1) The first-line treatment for partial epilepsy is carbamazepine monotherapy; gabapentin monotherapy is an alternative, given its lower risk of drug-drug interactions." | 1.33 | Pregabalin: new drug. Very similar to gabapentin. ( , 2005) |
| " Amitriptyline did not attenuate STZ-induced mechanical allodynia, even after chronic administration of high doses." | 1.33 | Adverse effects of gabapentin and lack of anti-allodynic efficacy of amitriptyline in the streptozotocin model of painful diabetic neuropathy. ( Bourin, C; Chen, P; Hogan, JB; Leet, JE; Lindner, MD; Machet, F; McElroy, JF; Stock, DA, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (15.00) | 18.7374 |
| 1990's | 13 (21.67) | 18.2507 |
| 2000's | 17 (28.33) | 29.6817 |
| 2010's | 16 (26.67) | 24.3611 |
| 2020's | 5 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Tesfaye, S | 3 |
| Sloan, G | 1 |
| Petrie, J | 2 |
| White, D | 2 |
| Bradburn, M | 2 |
| Julious, S | 2 |
| Rajbhandari, S | 1 |
| Sharma, S | 1 |
| Rayman, G | 1 |
| Gouni, R | 2 |
| Alam, U | 1 |
| Cooper, C | 2 |
| Loban, A | 2 |
| Sutherland, K | 2 |
| Glover, R | 1 |
| Waterhouse, S | 1 |
| Turton, E | 1 |
| Horspool, M | 1 |
| Gandhi, R | 1 |
| Maguire, D | 1 |
| Jude, EB | 1 |
| Ahmed, SH | 1 |
| Vas, P | 1 |
| Hariman, C | 1 |
| McDougall, C | 1 |
| Devers, M | 1 |
| Tsatlidis, V | 1 |
| Johnson, M | 1 |
| Rice, ASC | 1 |
| Bouhassira, D | 1 |
| Bennett, DL | 1 |
| Selvarajah, D | 2 |
| Barry, HC | 1 |
| Saul, H | 1 |
| Deeney, B | 1 |
| Imison, C | 1 |
| Eissa, RG | 1 |
| Eissa, NG | 1 |
| Eissa, RA | 1 |
| Diab, NH | 1 |
| Abdelshafi, NA | 1 |
| Shaheen, MA | 1 |
| Elsabahy, M | 1 |
| Hammad, SK | 1 |
| Srinivasan, A | 1 |
| Dutta, P | 3 |
| Bansal, D | 3 |
| Chakrabarti, A | 3 |
| Bhansali, AK | 1 |
| Hota, D | 4 |
| Chaudhry, M | 1 |
| Alessandrini, M | 1 |
| Rademan, J | 1 |
| Dodgen, TM | 1 |
| Steffens, FE | 1 |
| van Zyl, DG | 1 |
| Gaedigk, A | 1 |
| Pepper, MS | 1 |
| Bortolami, O | 1 |
| Bowler, H | 1 |
| Swaby, L | 1 |
| Hall, GC | 1 |
| Morant, SV | 1 |
| Carroll, D | 1 |
| Gabriel, ZL | 1 |
| McQuay, HJ | 1 |
| Sokov, EL | 2 |
| Kornilova, LE | 2 |
| Artiukov, OP | 1 |
| Anderson, SG | 1 |
| Malipatil, NS | 1 |
| Roberts, H | 1 |
| Dunn, G | 1 |
| Heald, AH | 1 |
| Hearn, L | 1 |
| Moore, RA | 1 |
| Derry, S | 1 |
| Wiffen, PJ | 1 |
| Phillips, T | 1 |
| Sawynok, J | 1 |
| Zinger, C | 1 |
| Tripathi, CD | 1 |
| Mehta, AK | 1 |
| Yadav, AM | 1 |
| Snyder, MJ | 1 |
| Gibbs, LM | 1 |
| Lindsay, TJ | 1 |
| Ziegler, D | 1 |
| Bhansali, A | 3 |
| Mahmood, D | 1 |
| Akhtar, M | 1 |
| Vohora, D | 1 |
| Khanam, R | 1 |
| Varsavsky, M | 1 |
| Quesada Charneco, M | 1 |
| Rozas Moreno, P | 1 |
| Kaur, H | 1 |
| Kopsky, DJ | 1 |
| Hesselink, JM | 1 |
| Shenoy, AM | 1 |
| Boyle, J | 1 |
| Eriksson, ME | 1 |
| Gribble, L | 1 |
| Johnsen, S | 1 |
| Coppini, DV | 1 |
| Kerr, D | 1 |
| Arsiukhin, NA | 1 |
| Nozdriukhina, NV | 1 |
| Ulugol, A | 1 |
| Karadag, HC | 1 |
| Tamer, M | 1 |
| Firat, Z | 1 |
| Aslantas, A | 1 |
| Dokmeci, I | 1 |
| Hong, HB | 1 |
| Xu, RJ | 1 |
| Nøkleby, K | 1 |
| Berg, TJ | 1 |
| Raskin, J | 2 |
| Smith, TR | 2 |
| Wong, K | 1 |
| Pritchett, YL | 2 |
| D'Souza, DN | 2 |
| Iyengar, S | 2 |
| Wernicke, JF | 2 |
| Grewal, J | 1 |
| Bril, V | 1 |
| Lewis, GF | 1 |
| Lewis, G | 1 |
| Perkins, BA | 1 |
| Lindner, MD | 1 |
| Bourin, C | 1 |
| Chen, P | 1 |
| McElroy, JF | 1 |
| Leet, JE | 1 |
| Hogan, JB | 1 |
| Stock, DA | 1 |
| Machet, F | 1 |
| Wu, EQ | 1 |
| Birnbaum, HG | 1 |
| Mareva, MN | 1 |
| Le, TK | 2 |
| Robinson, RL | 1 |
| Rosen, A | 1 |
| Gelwicks, S | 1 |
| Cayley, WE | 1 |
| Jose, VM | 1 |
| Pandhi, P | 1 |
| Baglioni, P | 1 |
| Govindan, J | 1 |
| Khan, A | 1 |
| Wang, F | 1 |
| Chappell, AS | 1 |
| Beard, SM | 1 |
| McCrink, L | 1 |
| Garcia-Cebrian, A | 1 |
| Monz, B | 1 |
| Malik, RA | 1 |
| Watson, CP | 1 |
| Mitas, JA | 1 |
| Mosley, CA | 1 |
| Drager, AM | 1 |
| Battla, H | 1 |
| Silverblatt, CW | 1 |
| Gade, GN | 1 |
| Hofeldt, FD | 1 |
| Treece, GL | 1 |
| Kerstein, MD | 1 |
| Polsky, S | 1 |
| Klein, M | 1 |
| Mahoney, JE | 1 |
| Gray, SL | 1 |
| Carnes, M | 1 |
| Bertherat, J | 1 |
| Netter, JM | 1 |
| Timsit, J | 1 |
| Chanson, P | 1 |
| Blumberg-Tick, J | 1 |
| Guillausseau, PJ | 1 |
| Warnet, A | 1 |
| Lubetzki, J | 1 |
| Bryson, HM | 1 |
| Wilde, MI | 1 |
| Vrethem, M | 1 |
| Boivie, J | 1 |
| Arnqvist, H | 1 |
| Holmgren, H | 1 |
| Lindström, T | 1 |
| Thorell, LH | 1 |
| Kumar, D | 2 |
| Alvaro, MS | 1 |
| Julka, IS | 2 |
| Marshall, HJ | 1 |
| Joss, JD | 1 |
| Morello, CM | 1 |
| Leckband, SG | 1 |
| Stoner, CP | 1 |
| Moorhouse, DF | 1 |
| Sahagian, GA | 1 |
| Dallocchio, C | 1 |
| Buffa, C | 1 |
| Mazzarello, P | 1 |
| Chiroli, S | 1 |
| Rawn, T | 1 |
| Papoushek, C | 1 |
| Evans, MF | 1 |
| Alvaro, M | 1 |
| Davis, JL | 1 |
| Lewis, SB | 1 |
| Gerich, JE | 1 |
| Kaplan, RA | 1 |
| Schultz, TA | 1 |
| Wallin, JD | 1 |
| Max, MB | 2 |
| Lynch, SA | 1 |
| Muir, J | 1 |
| Shoaf, SE | 1 |
| Smoller, B | 2 |
| Dubner, R | 2 |
| Egbunike, IG | 1 |
| Chaffee, BJ | 1 |
| Young, RJ | 1 |
| Clarke, BF | 1 |
| Culnane, M | 1 |
| Schafer, SC | 1 |
| Gracely, RH | 1 |
| Walther, DJ | 1 |
| Mendel, CM | 1 |
| Klein, RF | 1 |
| Chappell, DA | 1 |
| Dere, WH | 1 |
| Gertz, BJ | 1 |
| Karam, JH | 1 |
| Lavin, TN | 1 |
| Grunfeld, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Direct Current Neuromuscular Electrical Stimulation on Physical Therapy Treatment of Peripheral Neuropathy[NCT05442021] | 148 participants (Actual) | Interventional | 2022-08-01 | Completed | |||
| The Benefits of Astaxanthin as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient: Randomized Clinical Trial[NCT04689984] | Phase 2/Phase 3 | 60 participants (Anticipated) | Interventional | 2020-11-03 | Recruiting | ||
| The Effect of Foot and Ankle Exercise on Pain and Quality of Life in Patients With Diabetic Neuropathy[NCT05670600] | 100 participants (Actual) | Interventional | 2021-07-19 | Completed | |||
| A Double-blind, Randomised, Parallel Groups Investigation Into the Effects of Pregabalin, Duloxetine and Amitriptyline on Aspects of Pain, Sleep, and Next Day Performance in Patients Suffering From Diabetic Peripheral Neuropathy[NCT00370656] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2007-02-28 | Completed | ||
| A Phase I/II, Randomized, Study for Diabetic Macular Edema Using 0.3mg Ranibizumab Combined With Targeted PRP Monthly for 4 Months,Then PRN vs. 0.3mg Ranibizumab 4 Months Monotherapy, Then as Needed(DME-AntiVEgf) DAVE[NCT01552408] | Phase 1/Phase 2 | 29 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Enhancing Functional and Cognitive Performances in People With Amputation and Peripheral Neuropathy Through the Restoration of Sensory Feedback in Real World and Virtual Reality Environments[NCT04217005] | 20 participants (Anticipated) | Interventional | 2019-12-13 | Recruiting | |||
| Management of Chronic Pain in Rehabilitation Project I - Management of Chronic Pain in Persons With Spinal Cord Injury[NCT00006428] | Phase 4 | 100 participants | Interventional | 1996-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean change in peripheral visual field as measured by Goldmann visual field at screen and Month 36 in the ranibizumab and targeted PRP with ranibizumab cohorts. (NCT01552408)
Timeframe: 36 Months
| Intervention | degrees squared (Mean) |
|---|---|
| 0.3 mg Ranibizumab | -215 |
| Targeted PRP With 0.3 mg Ranibizumab | -1723 |
Evaluate the mean change over time in ETDRS BCVA in the ranibizumab and targeted PRP with ranibizumab cohorts through Month 36. (NCT01552408)
Timeframe: 36 Months
| Intervention | letters (Mean) |
|---|---|
| 0.3 mg Ranibizumab | 13.9 |
| Targeted PRP With 0.3 mg Ranibizumab | 8.2 |
Percentage of patients with persistent macular edema post-intravitreal injection in the ranibizumab and targeted PRP with ranibizumab cohorts. (NCT01552408)
Timeframe: Month 36
| Intervention | Participants (Count of Participants) |
|---|---|
| 0.3 mg Ranibizumab | 9 |
| Targeted Pan-retinal Photocoagulation With 0.3 mg Ranibizumab | 12 |
Assess the number of ranibizumab injections in the ranibizumab and targeted panretinal photocoagulation (PRP) with ranibizumab cohorts through Month 36. (NCT01552408)
Timeframe: 36 Months
| Intervention | injections (Mean) |
|---|---|
| 0.3 mg Ranibizumab | 24.4 |
| Targeted PRP With 0.3 mg Ranibizumab | 27.1 |
Determine percentage of patients who experience a gain of 15 or more letters from Baseline to Month 12, 24, and 36 in ETDRS BCVA in the ranibizumab and targeted PRP with ranibizumab cohorts. (NCT01552408)
Timeframe: Month 12, 24, and 36
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Month 12 | Month 24 | Month 36 | |
| 0.3 mg Ranibizumab | 10 | 10 | 9 |
| Targeted PRP With 0.3 mg Ranibizumab | 5 | 6 | 5 |
Evaluate mean change in central retinal thickness in the ranibizumab and targeted PRP with ranibizumab cohorts over time through Month 12, 24, and 36 as assessed by high resolution OCT's. (NCT01552408)
Timeframe: Month 12, 24, and 36
| Intervention | microns (Mean) | ||
|---|---|---|---|
| Month 12 | Month 24 | Month 36 | |
| 0.3 mg Ranibizumab | -301 | -296 | -302 |
| Targeted PRP With 0.3 mg Ranibizumab | -161 | -169 | -152 |
Incidence and severity of ocular and non-ocular adverse events (AE's) in the monotherapy and combination cohorts through Month 36. (NCT01552408)
Timeframe: 36 Months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Participants Experiencing Serious Ocular AE | Participants Experiencing Serious Systemic AE | |
| 0.3 mg Ranibizumab | 2 | 7 |
| Targeted PRP With 0.3 mg Ranibizumab | 1 | 9 |
Percentage of patients in the ranibizumab and targeted PRP with ranibizumab cohorts who experience a loss of 15 or more letters from Baseline to Month 12, 24, and 36 in ETDRS BCVA. (NCT01552408)
Timeframe: Month 12, 24, and 36
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| 12 Months | 24 Months | 36 Months | |
| 0.3 mg Ranibizumab | 0 | 0 | 0 |
| Targeted PRP With 0.3 mg Ranibizumab | 0 | 1 | 1 |
10 reviews available for amitriptyline and Diabetic Neuropathies
| Article | Year |
|---|---|
Desipramine for neuropathic pain in adults.
Topics: Aged; Amitriptyline; Analgesics; Antidepressive Agents, Tricyclic; Chronic Pain; Clomipramine; Desip | 2014 |
Treating Painful Diabetic Peripheral Neuropathy: An Update.
Topics: Administration, Topical; Amines; Amitriptyline; Analgesics; Analgesics, Opioid; Anesthetics, Local; | 2016 |
Treating Painful Diabetic Peripheral Neuropathy: An Update.
Topics: Administration, Topical; Amines; Amitriptyline; Analgesics; Analgesics, Opioid; Anesthetics, Local; | 2016 |
Treating Painful Diabetic Peripheral Neuropathy: An Update.
Topics: Administration, Topical; Amines; Amitriptyline; Analgesics; Analgesics, Opioid; Anesthetics, Local; | 2016 |
Treating Painful Diabetic Peripheral Neuropathy: An Update.
Topics: Administration, Topical; Amines; Amitriptyline; Analgesics; Analgesics, Opioid; Anesthetics, Local; | 2016 |
Painful diabetic neuropathy: advantage of novel drugs over old drugs?
Topics: Amitriptyline; Analgesics; Antioxidants; Antipruritics; Capsaicin; Chronic Disease; Diabetic Neuropa | 2009 |
High doses of topical amitriptyline in neuropathic pain: two cases and literature review.
Topics: Administration, Topical; Adult; Amitriptyline; Analgesics, Non-Narcotic; Diabetic Neuropathies; Huma | 2012 |
[Progress on painful diabetic peripheral neuropathy treated by integrative medicine].
Topics: Amines; Amitriptyline; Analgesics; Animals; Antidepressive Agents, Tricyclic; Blood Glucose; Cyclohe | 2005 |
[Diabetic neuropathy--a clinical review].
Topics: Amitriptyline; Analgesics, Non-Narcotic; Diabetic Foot; Diabetic Neuropathies; Diagnosis, Differenti | 2005 |
Antidepressants for the treatment of neuropathic pain.
Topics: Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Diabetic Neuropathies; Humans; Male; Neuralgi | 2006 |
Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states.
Topics: Aged; Amitriptyline; Analgesics, Non-Narcotic; Animals; Antidepressive Agents, Tricyclic; Chronic Di | 1996 |
Tricyclic antidepressant use in diabetic neuropathy.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Desipramine; Diabetic Neuropathies; Humans | 1999 |
Antidepressants in the management of chronic pain syndromes.
Topics: Amitriptyline; Antidepressive Agents; Arthritis; Back Pain; Chronic Disease; Diabetic Neuropathies; | 1990 |
22 trials available for amitriptyline and Diabetic Neuropathies
| Article | Year |
|---|---|
Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomise
Topics: Amitriptyline; Analgesics; Cross-Over Studies; Diabetes Mellitus; Diabetic Neuropathies; Double-Blin | 2022 |
Combination therapy for painful diabetic neuropathy is safe and effective.
Topics: Amitriptyline; Analgesics; Diabetes Mellitus; Diabetic Neuropathies; Double-Blind Method; Duloxetine | 2023 |
Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: A randomized, double-blind, active-control, crossover clinical trial.
Topics: Amitriptyline; Analgesics, Non-Narcotic; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Neu | 2021 |
Multicentre, double-blind, crossover trial to identify the Optimal Pathway for TreatIng neurOpathic paiN in Diabetes Mellitus (OPTION-DM): study protocol for a randomised controlled trial.
Topics: Amitriptyline; Analgesics; Cross-Over Studies; Diabetic Neuropathies; Double-Blind Method; Drug Ther | 2018 |
[Intraosseous blocks in the treatment of symmetrical distal diabetic polyneuropathy].
Topics: Aged; Amitriptyline; Analgesics, Non-Narcotic; Anesthetics, Local; Diabetic Neuropathies; Female; Fo | 2013 |
Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial.
Topics: Amitriptyline; Analgesics, Non-Narcotic; Diabetic Neuropathies; Dose-Response Relationship, Drug; Do | 2009 |
A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial.
Topics: Adolescent; Adult; Aged; Amitriptyline; Cross-Over Studies; Diabetic Neuropathies; Double-Blind Meth | 2011 |
Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life.
Topics: Aged; Amitriptyline; Diabetic Neuropathies; Double-Blind Method; Duloxetine Hydrochloride; Female; g | 2012 |
Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life.
Topics: Aged; Amitriptyline; Diabetic Neuropathies; Double-Blind Method; Duloxetine Hydrochloride; Female; g | 2012 |
Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life.
Topics: Aged; Amitriptyline; Diabetic Neuropathies; Double-Blind Method; Duloxetine Hydrochloride; Female; g | 2012 |
Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life.
Topics: Aged; Amitriptyline; Diabetic Neuropathies; Double-Blind Method; Duloxetine Hydrochloride; Female; g | 2012 |
[The complex treatment of the pain syndrome in diabetic distal polyneuropathy using intraosteal blockades].
Topics: Aged; Amitriptyline; Analgesia; Analgesics, Non-Narcotic; Bone and Bones; Combined Modality Therapy; | 2012 |
Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain.
Topics: Amines; Amitriptyline; Analysis of Variance; Cyclohexanecarboxylic Acids; Cyclohexanols; Diabetic Ne | 2006 |
Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain.
Topics: Adrenergic Uptake Inhibitors; Aged; Amines; Amitriptyline; Analgesia; Analgesics; Brain; Cohort Stud | 2006 |
Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy.
Topics: Adolescent; Adult; Aged; Algorithms; Amitriptyline; Analgesics, Non-Narcotic; Calcium Channel Blocke | 2007 |
An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain.
Topics: Acetaminophen; Amitriptyline; Analgesics; Carbamazepine; Diabetes Complications; Diabetic Neuropathi | 2007 |
Clinical trial of amitriptyline and fluphenazine in diabetic peripheral neuropathy.
Topics: Amitriptyline; Clinical Trials as Topic; Diabetic Neuropathies; Drug Therapy, Combination; Fluphenaz | 1981 |
A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics.
Topics: Adult; Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents, Tricyclic; Cross-Over Studies; | 1997 |
Diabetic peripheral neuropathy. Effectiveness of electrotherapy and amitriptyline for symptomatic relief.
Topics: Adult; Aged; Amitriptyline; Diabetic Neuropathies; Electric Stimulation Therapy; Female; Humans; Mal | 1998 |
Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain.
Topics: Acetates; Adrenergic Uptake Inhibitors; Aged; Amines; Amitriptyline; Analgesics; Cross-Over Studies; | 1999 |
Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study.
Topics: Acetates; Aged; Aged, 80 and over; Amines; Amitriptyline; Analgesics; Ataxia; Cyclohexanecarboxylic | 2000 |
Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Amitriptyline; Analgesics; Depression; Desipramine; Diabetic Neuropa | 1992 |
Pain relief in diabetic neuropathy: the effectiveness of imipramine and related drugs.
Topics: Adult; Aged; Amitriptyline; Clinical Trials as Topic; Clonazepam; Diabetic Neuropathies; Double-Blin | 1985 |
Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood.
Topics: Adult; Aged; Amitriptyline; Depression; Diabetic Neuropathies; Double-Blind Method; Female; Humans; | 1987 |
A trial of amitriptyline and fluphenazine in the treatment of painful diabetic neuropathy.
Topics: Adult; Amitriptyline; Clinical Trials as Topic; Diabetic Neuropathies; Double-Blind Method; Female; | 1986 |
28 other studies available for amitriptyline and Diabetic Neuropathies
| Article | Year |
|---|---|
Amitriptyline, Duloxetine, and Pregabalin Each Effective in Decreasing Pain From Diabetic Peripheral Neuropathy; Combinations Even Better.
Topics: Amitriptyline; Analgesics; Diabetes Mellitus; Diabetic Neuropathies; Duloxetine Hydrochloride; Human | 2023 |
Oral proniosomal amitriptyline and liraglutide for management of diabetic neuropathy: Exceptional control over hyperglycemia and neuropathic pain.
Topics: Amitriptyline; Animals; Blood Glucose; Diabetes Mellitus; Diabetic Neuropathies; Humans; Hyperglycem | 2023 |
Impact of CYP2D6 genotype on amitriptyline efficacy for the treatment of diabetic peripheral neuropathy: a pilot study.
Topics: Amitriptyline; Analgesics, Non-Narcotic; Cytochrome P-450 CYP2D6; Diabetic Neuropathies; Genotype; H | 2017 |
An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population.
Topics: Acetaminophen; Adolescent; Adult; Aged; Amines; Amitriptyline; Analgesics, Non-Narcotic; Analgesics, | 2013 |
Socioeconomic deprivation independently predicts symptomatic painful diabetic neuropathy in type 1 diabetes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amitriptyline; Analgesics; Biomarkers; Body Mass Index; | 2014 |
Topical amitriptyline and ketamine for post-herpetic neuralgia and other forms of neuropathic pain.
Topics: Administration, Topical; Amitriptyline; Analgesics; Animals; Diabetic Neuropathies; Drug Combination | 2016 |
Drug combinations in diabetic neuropathic pain: an experimental validation.
Topics: Amitriptyline; Analgesics; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Drug The | 2016 |
Comparison of antinociceptive and antidiabetic effects of sertraline and amitriptyline on streptozotocin-induced diabetic rats.
Topics: Amitriptyline; Analgesics; Animals; Antidepressive Agents, Tricyclic; Blood Glucose; Diabetes Mellit | 2010 |
[Urea as therapeutic option for the treatment of the syndrome of inappropriate antidiuretic hormone secretion].
Topics: Amitriptyline; Carbamazepine; Comorbidity; Demeclocycline; Diabetic Neuropathies; Diuretics; Furosem | 2011 |
Guidelines in practice: treatment of painful diabetic neuropathy.
Topics: Amitriptyline; Analgesics; Clinical Coding; Diabetic Neuropathies; gamma-Aminobutyric Acid; Humans; | 2012 |
Involvement of adenosine in the anti-allodynic effect of amitriptyline in streptozotocin-induced diabetic rats.
Topics: Adenosine; Amitriptyline; Analgesics; Animals; Antidepressive Agents, Tricyclic; Caffeine; Diabetes | 2002 |
Pregabalin: new drug. Very similar to gabapentin.
Topics: Amines; Amitriptyline; Anticonvulsants; Clinical Trials as Topic; Cost-Benefit Analysis; Cyclohexane | 2005 |
Objective evidence for the reversibility of nerve injury in diabetic neuropathic cachexia.
Topics: Adult; Amines; Amitriptyline; Analgesics; Antidepressive Agents, Tricyclic; Cachexia; Cyclohexanecar | 2006 |
Adverse effects of gabapentin and lack of anti-allodynic efficacy of amitriptyline in the streptozotocin model of painful diabetic neuropathy.
Topics: Amines; Amitriptyline; Animals; Cognition Disorders; Cyclohexanecarboxylic Acids; Diabetes Mellitus, | 2006 |
Career lifetime advances and key developments: diabetes.
Topics: Amines; Amitriptyline; Analgesics; Antidepressive Agents; Cyclohexanecarboxylic Acids; Diabetic Neur | 2007 |
Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK.
Topics: Amines; Amitriptyline; Antidepressive Agents; Cost-Benefit Analysis; Cyclohexanecarboxylic Acids; Di | 2008 |
Therapeutic window for amitriptyline analgesia.
Topics: Aged; Amitriptyline; Analgesics; Diabetic Neuropathies; Dose-Response Relationship, Drug; Humans; Mi | 1984 |
Diabetic neuropathic pain: control by amitriptyline and fluphenazine in renal insufficiency.
Topics: Adult; Aged; Amitriptyline; Diabetic Neuropathies; Drug Therapy, Combination; Female; Fluphenazine; | 1983 |
Diabetic neuropathic cachexia. Beneficial response to combination therapy with amitriptyline and fluphenazine.
Topics: Amitriptyline; Cachexia; Diabetic Neuropathies; Drug Therapy, Combination; Fluphenazine; Humans; Syn | 1980 |
Treating wounds associated with decreased sensibility.
Topics: Amitriptyline; Capsaicin; Diabetic Foot; Diabetic Neuropathies; Humans; Shoes; Skin Care | 1995 |
Prevention and treatment of the complications of diabetes mellitus.
Topics: Amitriptyline; Analgesics, Opioid; Diabetic Neuropathies; Humans; Pain | 1995 |
Prevention and treatment of the complications of diabetes mellitus.
Topics: Aged; Amitriptyline; Desipramine; Diabetic Neuropathies; Humans; Pain | 1995 |
[Diabetic thoracoabdominal neuropathy. Clinical and electrophysiological study with evaluation of the autonomic nervous system].
Topics: Abdominal Pain; Adult; Aged; Amitriptyline; Analgesics; Autonomic Nervous System Diseases; Chest Pai | 1993 |
Drugs for pain.
Topics: Acetaminophen; Administration, Oral; Amitriptyline; Analgesics; Analgesics, Non-Narcotic; Analgesics | 1998 |
Gabapentin or amitriptyline for painful diabetic neuropathy?
Topics: Acetates; Amines; Amitriptyline; Analgesics; Analgesics, Non-Narcotic; Clinical Trials as Topic; Cyc | 2000 |
Transcutaneous electrostimulation: emerging treatment for diabetic neuropathic pain.
Topics: Amitriptyline; Clinical Trials as Topic; Combined Modality Therapy; Diabetic Neuropathies; Humans; N | 1999 |
Peripheral diabetic neuropathy treated with amitriptyline and fluphenazine.
Topics: Adult; Aged; Amitriptyline; Diabetic Neuropathies; Drug Therapy, Combination; Female; Fluphenazine; | 1977 |
Amitriptyline and fluphenazine for painful diabetic neuropathy.
Topics: Amitriptyline; Diabetic Neuropathies; Fluphenazine; Humans; Pain; Placebos; Research Design | 1986 |